
Patrizio Giacomini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/530736/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM. PLoS ONE, 2008, 3, e2236.	1.1	345
2	Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 6719-6723.	3.3	124
3	Antibody–drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. Nanoscale, 2013, 5, 12278.	2.8	119
4	Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. Journal of Immunology, 1983, 130, 1462-6.	0.4	108
5	Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Research, 1983, 43, 660-8.	0.4	105
6	Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. Journal of Immunology, 1984, 133, 1649-55.	0.4	97
7	Expression of Endoplasmic Reticulum Aminopeptidases in EBV-B Cell Lines from Healthy Donors and in Leukemia/Lymphoma, Carcinoma, and Melanoma Cell Lines. Journal of Immunology, 2006, 176, 4869-4879.	0.4	88
8	Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin–Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements. Biomacromolecules, 2016, 17, 514-522.	2.6	88
9	Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non″ymphoid human tissues. Journal of Cellular Physiology, 2008, 216, 742-749.	2.0	85
10	Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice. Cancer Research, 1986, 46, 5772-8.	0.4	77
11	Human Leukocyte Antigen E Contributes to Protect Tumor Cells from Lysis by Natural Killer Cells. Neoplasia, 2011, 13, 822-IN14.	2.3	73
12	IRF1 and NF-kB Restore MHC Class I-Restricted Tumor Antigen Processing and Presentation to Cytotoxic T Cells in Aggressive Neuroblastoma. PLoS ONE, 2012, 7, e46928.	1.1	69
13	NF-κB, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells. Cancer Research, 2010, 70, 916-924.	0.4	65
14	Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing. Cancer Research, 2011, 71, 1597-1606.	0.4	64
15	Distinctive Features of the α1-Domain a Helix of HLA-C Heavy Chains Free of β2-Microglobulin. Human Immunology, 1996, 46, 69-81.	1.2	61
16	Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness. Journal of Controlled Release, 2016, 239, 10-18.	4.8	60
17	Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations. Journal of Experimental and Clinical Cancer Research, 2018, 37, 47.	3.5	60
18	High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. Journal of Translational Medicine, 2011, 9, 184.	1.8	55

#	Article	IF	CITATIONS
19	Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by γIFN treatment. Tissue Antigens, 2000, 56, 30-37.	1.0	47
20	Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). Anticancer Research, 1988, 8, 1153-61.	0.5	47
21	Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves. Biosensors and Bioelectronics, 2017, 92, 125-130.	5.3	41
22	Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review). International Journal of Oncology, 2018, 53, 1395-1434.	1.4	41
23	Production and Characterization of the Murine Monoclonal Antibody 2G10 to a Human T4-Tyrosinase Epitope. Journal of Investigative Dermatology, 1991, 96, 446-451.	0.3	40
24	HLA-E: Strong Association with β2-Microglobulin and Surface Expression in the Absence of HLA Class I Signal Sequence-Derived Peptides. Journal of Immunology, 2008, 181, 5442-5450.	0.4	37
25	Programmable Interactions of Functionalized Single Bioparticles in a Dielectrophoresis-Based Microarray Chip. Analytical Chemistry, 2013, 85, 8219-8224.	3.2	37
26	HLA heavy chains free of ß ₂ â€microglobulin: distribution in normal tissues and neoplastic lesions of nonâ€lymphoid origin and interferonâ€Î³ responsiveness. Tissue Antigens, 1997, 50, 555-566.	1.0	36
27	Expression of single-chain antibodies in transgenic plants. Vaccine, 2005, 23, 1823-1827.	1.7	36
28	A Single Bottleneck in HLA-C Assembly. Journal of Biological Chemistry, 2008, 283, 1267-1274.	1.6	36
29	Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time. Current Oncology, 2012, 19, 39-41.	0.9	34
30	Recombinant human IFN-gamma, but not IFN-alpha or IFN-beta, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism. Journal of Immunology, 1988, 140, 3073-81.	0.4	32
31	Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. Journal of the National Cancer Institute, 1983, 71, 439-47.	3.0	32
32	Production and Characterization of Murine mAbs to the Extracellular Domain of Human Neu Oncogene Product GP185HER2. Hybridoma, 1992, 11, 519-527.	0.9	31
33	Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. Journal of Immunology, 1985, 135, 696-702.	0.4	30
34	The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. Cancer Research, 2003, 63, 4119-27.	0.4	30
35	Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. , 1985, 31, 209-236.		29
36	Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncology, The, 2012, 13, e205-e211.	5.1	29

#	Article	IF	CITATIONS
37	T and NK cells: two sides of tumor immunoevasion. Journal of Translational Medicine, 2013, 11, 30.	1.8	29
38	The impact of monoclonal antibodies on the study of human malignant melanoma. Journal of Cutaneous Pathology, 1983, 10, 514-528.	0.7	28
39	Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. Journal of Translational Medicine, 2006, 4, 39.	1.8	28
40	A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery. Cancers, 2020, 12, 2410.	1.7	27
41	Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating <i>EWS-FLI1</i> fusion transcripts. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877433.	1.4	26
42	Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA). Journal of Experimental and Clinical Cancer Research, 2018, 37, 124.	3.5	25
43	Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. International Journal of Cancer, 1990, 46, 539-545.	2.3	24
44	Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons. Cancer Immunology, Immunotherapy, 1991, 32, 382-390.	2.0	24
45	A melanoma immune response signature including Human Leukocyte Antigen‣. Pigment Cell and Melanoma Research, 2014, 27, 103-112.	1.5	24
46	Direct plasmonic detection of circulating RAS mutated DNA in colorectal cancer patients. Biosensors and Bioelectronics, 2020, 170, 112648.	5.3	24
47	Unknown primary tumors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1816, 13-24.	3.3	23
48	Distamycin inhibits the binding of a nuclear factor to the -278/-256 upstream sequence of the human HLA-DRI± gene. Biochemical Pharmacology, 1991, 41, 497-502.	2.0	22
49	Binding of Epstein-Barr virus nuclear antigen 1 to DNA: inhibition by distamycin and two novel distamycin analogues. European Journal of Pharmacology, 1994, 267, 143-149.	2.7	22
50	Conformation and surface expression of free HLA-CW1 heavy chains in the absence of β2-microglobulin. Human Immunology, 1997, 53, 23-33.	1.2	22
51	cDNA-array profiling of melanomas and paired melanocyte cultures. Journal of Cellular Physiology, 2006, 207, 697-705.	2.0	22
52	HLA-A, -B, -C Expression in Colon Carcinoma Mimics That of the Normal Colonic Mucosa and is Prognostically Relevant. American Journal of Surgical Pathology, 2007, 31, 76-84.	2.1	22
53	Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. International Journal of Molecular Sciences, 2021, 22, 3837.	1.8	22
54	Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens. Journal of Cutaneous Pathology, 1983, 10, 225-237.	0.7	21

#	Article	IF	CITATIONS
55	Heterogeneous distribution of actin, myosin, fibronectin and basement membrane antigens in primary and metastatic human breast cancer. Virchows Archiv A, Pathological Anatomy and Histopathology, 1984, 405, 69-83.	1.4	21
56	Lack of correlation between hypomethylation and expression of the HLA-DRα gene. European Journal of Immunology, 1986, 16, 365-369.	1.6	20
57	Class I HLA Folding and Antigen Presentation in β2-Microglobulin-Defective Daudi Cells. Journal of Immunology, 2009, 182, 3609-3617.	0.4	20
58	Multiple epitope recognition: An approach to improved radioimmunodetection of tumor-associated antigens. International Journal of Cancer, 1987, 39, 729-736.	2.3	19
59	Detection of Tumor DNA in Human Plasma with a Functional PLL-Based Surface Layer and Plasmonic Biosensing. ACS Sensors, 2021, 6, 2307-2319.	4.0	19
60	Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 69.	3.5	18
61	Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. British Journal of Cancer, 1999, 80, 639-649.	2.9	17
62	Functional expression of a single-chain antibody specific for the HER2 human oncogene in a bacterial reducing environment. Protein Expression and Purification, 2005, 44, 10-15.	0.6	17
63	Lysis-on-Chip of Single Target Cells following Forced Interaction with CTLs or NK Cells on a Dielectrophoresis-Based Array. Journal of Immunology, 2013, 191, 3545-3552.	0.4	17
64	Analysis of the NIH Workshop Monoclonal Antibodies to Human Melanoma Antigens. Hybridoma, 1982, 1, 473-482.	0.9	16
65	A third polypeptide associated with heavy and light chain subunits of class I HLA antigens in immune interferon-treated human melanoma cells. European Journal of Immunology, 1985, 15, 946-951.	1.6	16
66	mAb KUL/05 IDENTIFIES A DENATURATION-RESISTANT DETERMINANT SHARED BY CLASS II MHC PRODUCTS DR, DQ AND DP. International Journal of Immunogenetics, 1989, 16, 203-216.	1.2	16
67	Gene variants associated to malignant thyroid disease in familial adenomatous polyposis: A novel APC germline mutation. Journal of Endocrinological Investigation, 2010, 33, 603-606.	1.8	16
68	Effect of recombinant human fibroblast interferon and mezerein on growth, differentiation, immune interferon binding and tumor associated antigen expression in human melanoma cells. Anticancer Research, 1986, 6, 765-74.	0.5	16
69	Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. In Vivo, 2009, 23, 347-52.	0.6	16
70	Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts. Journal of Experimental and Clinical Cancer Research, 2015, 34, 98.	3.5	15
71	Ontogeny of murine I-Ak antigens in tissue of nonlymphoid origin. Immunogenetics, 1981, 14, 359-365.	1.2	14
72	Some evidence for the in vivo functional activation of suppressor T cells in asymptomatic patients with hemophilia A receiving factor VIII concentrates. Clinical Immunology and Immunopathology, 1985, 34, 27-38.	2.1	14

#	Article	IF	CITATIONS
73	Regulation of the Expression of Class II Genes of the Human Major Histocompatibility Complex in Tumor Cells. Annals of the New York Academy of Sciences, 1987, 511, 292-307.	1.8	14
74	Human HLA-DRα gene: a rare oligonucleotide (GTATA) identifies an upstream sequence required for nuclear protein binding. FEBS Letters, 1990, 268, 51-54.	1.3	14
75	Membrane expression of HLA-Cw4 free chains in activated T cells of transgenic mice. Immunogenetics, 1995, 42, 368-75.	1.2	13
76	High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors. Journal of Experimental and Clinical Cancer Research, 2021, 40, 63.	3.5	13
77	Impaired Assembly Results in the Accumulation of Multiple HLA-C Heavy Chain Folding Intermediates. Journal of Immunology, 2005, 175, 6651-6658.	0.4	11
78	Monoclonal antibodies to HLAâ€E bind epitopes carried by unfolded β ₂ mâ€free heavy chains. European Journal of Immunology, 2015, 45, 2356-2364.	1.6	11
79	Sub-apoptotic dosages of pro-oxidant vitamin cocktails sensitize human melanoma cells to NK cell lysis. Oncotarget, 2015, 6, 31039-31049.	0.8	11
80	Differential Susceptibility to Modulation by Recombinant Immune Interferon of HLA-DR and -DQ Antigens Synthesized by Melanoma COLO 38 Cells. Hybridoma, 1986, 5, 277-288.	0.9	10
81	Bloch Surface Waves Biosensors for High Sensitivity Detection of Soluble ERBB2 in a Complex Biological Environment. Biosensors, 2017, 7, 33.	2.3	10
82	Lymphoid stroma of Warthin's tumor: Phenotypic analogies with gut-associated lymphoid tissue. Clinical Immunology and Immunopathology, 1985, 34, 39-47.	2.1	9
83	Tissue-specific expression of theHLA-DRA gene in transgenic mice. Immunogenetics, 1991, 34, 385-391.	1.2	9
84	Distamycin analogues with improved sequence-specific DNA binding activities. Biochemical Pharmacology, 1994, 48, 1583-1591.	2.0	9
85	Sequencing of an upstream region of the human HLA-DRA gene containing X' and Y' boxes. Nucleic Acids Research, 1995, 23, 1671-1678.	6.5	9
86	An ID card for tumour cell lines: HLA typing can help. Lancet Oncology, The, 2001, 2, 658.	5.1	9
87	Bioassay engineering: a combined label-free and fluorescence approach to optimize HER2 detection in complex biological media. Analytical and Bioanalytical Chemistry, 2020, 412, 3509-3517.	1.9	9
88	Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. Molecular Cancer, 2021, 20, 151.	7.9	9
89	METHYLATION PATTERN OF THE HLA-DR? GENE IN HUMAN TISSUES. International Journal of Immunogenetics, 1990, 17, 51-66.	1.2	7
90	First-trimester human trophoblast is class II major histocompatibility complex mRNA+/antigenâ^'. Human Immunology, 1994, 39, 281-289.	1.2	7

#	Article	IF	CITATIONS
91	DRα:Eβ heterodimers in DRA transgenic mice hinder expression of Eα:Eβ molecules and are more efficient in antigen presentation. International Immunology, 1995, 7, 1927-1938.	1.8	7
92	N-Linked Glycosylation Selectively Regulates the Generic Folding of HLA-Cw1. Journal of Biological Chemistry, 2008, 283, 16469-16476.	1.6	7
93	Human melanoma-associated antigens identified with monoclonal antibodies. Research in Clinic and Laboratory, 1982, 12, 517-38.	0.3	7
94	Transgenic mice mimic the methylation pattern of the human HLA-DRα gene. Biochemical and Biophysical Research Communications, 1991, 175, 459-466.	1.0	6
95	Membrane Compartmentalization of Melanosomal gp75. Journal of Investigative Dermatology, 1992, 98, 340-342.	0.3	6
96	Characterization of a Major Histocompatibility Complex Class II X-Box-Binding Protein Enhancing Tat-Induced Transcription Directed by the Human Immunodeficiency Virus Type 1 Long Terminal Repeat. Journal of Virology, 2000, 74, 8989-9001.	1.5	6
97	HLA-E and the origin of immunogenic self HLA epitopes. Molecular Immunology, 2010, 47, 1661-1662.	1.0	6
98	Comment on "Influence of HLA-C Expression Level on HIV Controlâ€: Science, 2013, 341, 1175-1175.	6.0	5
99	Molecular heterogeneity and shedding of a high-molecular-mass melanoma-associated antigen identified with monoclonal antibodies. Clinical Chemistry, 1982, 28, 2347-50.	1.5	5
100	Modular usage of the HLA-DRA promoter in extra-hematopoietic and hematopoietic cell types of transgenic mice. FEBS Journal, 2005, 272, 3214-3226.	2.2	4
101	Isolation of viable melanoma cells from surgically removed lesions using dishes coated with monoclonal antibody to a high molecular weight melanoma associated antigen. Journal of Immunological Methods, 1983, 62, 337-346.	0.6	3
102	Analysis of the human HLA-DRA gene upstream region: Evidence for a stem-loop array directed by nuclear factors. Biochimie, 1999, 81, 219-228.	1.3	3
103	HLA-A, -B, -C Genotyping and Expression in Human Nonlymphoid Tumor Cell Lines. Journal of Immunotherapy, 1999, 22, 7-15.	1.2	3
104	CG Dinucleotides of class II MHC genes are mutation hot-spots. Cytotechnology, 1988, 1, 133-138.	0.7	2
105	Methylation state of the human HLA-DRA gene in T-lymphocytes and B-lymphocytes of transgenic mice. Lack of methylation at one 5'-GCGC site is not required for gene expression. FEBS Journal, 1993, 218, 485-492.	0.2	2
106	Methylation State of Cellular Genes and Oncogenes as a Marker of Malignancy in Human Carcinomas. Tumori, 1989, 75, 321-328.	0.6	1
107	Antigenic modulation of metastatic breast and ovary carcinoma cells by intracavitary injection of IFN-I±. British Journal of Cancer, 1992, 66, 342-344.	2.9	1
108	Combined label-free/fluorescence platform based on Bloch surface waves biochips for cancer biomarker detection. , 2018, , .		1

7

#	Article	IF	CITATIONS
109	Metastatic capacity of some murine tumors and TSP-180 expression*. Cell Biology International Reports, 1986, 10, 194-194.	0.7	Ο
110	Quantitation of mRNA and protein products of the Ha-ras-1 proto-oncogene. Breast Cancer Research and Treatment, 1990, 16, 287-289.	1.1	0
111	Methylation state of the human HLA-DRa gene in transgenic mice. Cytotechnology, 1991, 5, 55-56.	0.7	0
112	Identification of a novel DNase I hypersensitive site within the far upstream region of the human HLA-DRA gene. International Journal of Molecular Medicine, 2003, 12, 929.	1.8	0
113	Molecular Immunoevasion Strategies Targeting Antigen Processing and Presentation. , 2016, , 279-296.		0
114	Photobleaching at the Surface of 1D-photonic Crystal Biochips. , 2019, , .		0
115	Label-free and fluorescence photonic crystal biochips for early cancer biomarker detection. , 2019, , .		0
116	Optical multiplexed bioassays on photonic crystals for breast cancer biomarker detection. EPJ Web of Conferences, 2021, 255, 13003.	0.1	0